4 agosto 2025 – Ypsomed Holding AG (SIX: YPSN) announced that the sale of the Ypsomed Diabetes Care business to TecMed AG, initially announced on 22 April 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies.

Walder Wyss advised Ypsomed on the carve-out of the diabetes care business and the sale to TecMed AG. The team was led by Hans-Jakob Diem (Partner, Corporate/M&A) and Dominik Hohler (Partner, Corporate/M&A) and included Letizia Schlegel (Senior Associate, Corporate/M&A), Michael Kissling (Senior Associate, Corporate/M&A), Michael Isler (Partner, IP/Data Protection and Regulatory), Kento Reutimann (Associate, IP/Data Protection), Florian Iten (Associate, Corporate/M&A), Valentin Wiesner (Managing Associate, Finance) and Valentin Freiermuth (Associate, Finance).